Welcome to our dedicated page for TenX Keane Acquisition news (Ticker: TENKR), a resource for investors and traders seeking the latest updates and insights on TenX Keane Acquisition stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TenX Keane Acquisition's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TenX Keane Acquisition's position in the market.
TenX Keane Acquisition (Nasdaq: TENKU) faced a trading halt on August 7, 2024, due to additional information requested by Nasdaq following unusual trading activity. The company is working with Nasdaq to lift the halt. Meanwhile, TenX shareholders approved the merger with Citius Oncology on August 2, 2024. The post-merger entity is expected to trade as Citius Oncology, Inc. (CTOR) on Nasdaq.
In a related development, Citius Pharmaceuticals (Nasdaq: CTXR) announced FDA approval for LYMPHIR™, a treatment for relapsed or refractory cutaneous T-cell lymphoma. TenX and Citius Pharma are progressing towards closing the business combination in the near future.
TenX Keane Acquisition shareholders have approved the merger with Citius Pharmaceuticals' oncology subsidiary to form Citius Oncology, Inc. The vote took place at an extraordinary general meeting on August 2, 2024. The newly combined company is expected to trade on Nasdaq under the Citius Oncology name. This merger aims to support the commercialization of LYMPHIR, pending approval, and explore additional oncology assets. The transaction is anticipated to provide Citius Oncology with improved access to public equity markets. Subject to closing conditions, the merger is expected to be completed in the coming weeks. This strategic move positions Citius Oncology to advance its oncology pipeline and potentially strengthen its market presence in the biopharmaceutical sector.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
TenX Keane Acquisition (NASDAQ:TENKU) announced the closing of its initial public offering (IPO) of 6,600,000 units at an offering price of $10.00 per unit, generating $66,000,000 in gross proceeds. The IPO included a partial exercise of the underwriter's over-allotment option for 600,000 units. Each unit consists of one ordinary share and one right, with rights entitling holders to receive two-tenths of one share upon the initial business combination. The units began trading on NASDAQ under the symbol TENKU on October 14, 2022.
TenX Keane Acquisition has successfully priced its initial public offering (IPO) at $10.00 per unit, totaling 6,000,000 units. Each unit includes one ordinary share and a right to receive two-tenths of one ordinary share upon completing the Company's initial business combination. Trading under the ticker symbol TENKU begins on October 14, 2022, on the Nasdaq Global Market. The underwriter, Maxim Group LLC, has a 45-day option to purchase an additional 900,000 units. The offering is slated to close on October 18, 2022, pending customary closing conditions.